Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Subject with a history of moderate to severe atopic dermatitis who participated in the preceding ASN002AD-201 and ASN002AD-101 study~* Subject must be a candidate for prolonged open label ASN002/gusacitinib treatment according to the investigator's judgment.~* Subject has been using an emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily throughout the study.~* Men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse~* Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.~* Subjects must be willing to comply with all study procedures and must be available for the duration of the study.~* Subject has a body mass index (BMI) ≤ 38 kg/m2.~Exclusion Criteria~* Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.~* Subject has clinically infected atopic dermatitis.~* A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer~* Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.~* Subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.~* Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASN002 40 mg (Type: EXPERIMENTAL): ASN002 40 mg
- ASN002 60 mg (Type: EXPERIMENTAL): ASN002 60 mg
- ASN002 80 mg (Type: EXPERIMENTAL): ASN002 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).